AU2002360586A8 - Flj1115 as modifier of the apaf-1 pathway and methods of use - Google Patents

Flj1115 as modifier of the apaf-1 pathway and methods of use

Info

Publication number
AU2002360586A8
AU2002360586A8 AU2002360586A AU2002360586A AU2002360586A8 AU 2002360586 A8 AU2002360586 A8 AU 2002360586A8 AU 2002360586 A AU2002360586 A AU 2002360586A AU 2002360586 A AU2002360586 A AU 2002360586A AU 2002360586 A8 AU2002360586 A8 AU 2002360586A8
Authority
AU
Australia
Prior art keywords
flj1115
apaf
modifier
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002360586A
Other versions
AU2002360586A1 (en
Inventor
Roel P Funke
Monique Nicoll
Tak Hung
Danxi Li
Michael Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2002360586A1 publication Critical patent/AU2002360586A1/en
Publication of AU2002360586A8 publication Critical patent/AU2002360586A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002360586A 2001-12-13 2002-12-12 FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE Abandoned AU2002360586A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34031301P 2001-12-13 2001-12-13
US60/340,313 2001-12-13
US35744702P 2002-02-15 2002-02-15
US60/357,447 2002-02-15
PCT/US2002/039867 WO2003052069A2 (en) 2001-12-13 2002-12-12 FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE

Publications (2)

Publication Number Publication Date
AU2002360586A1 AU2002360586A1 (en) 2003-06-30
AU2002360586A8 true AU2002360586A8 (en) 2003-06-30

Family

ID=26992055

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002360586A Abandoned AU2002360586A1 (en) 2001-12-13 2002-12-12 FLJ1115 AS MODIFIER OF THE Apaf-1 PATHWAY AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2002360586A1 (en)
WO (1) WO2003052069A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228603B1 (en) * 1997-05-22 2001-05-08 The Burnham Institute Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
JP2001523977A (en) * 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Activator of APAF-1, CED-4 human homolog, caspase-3
US6403765B1 (en) * 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof

Also Published As

Publication number Publication date
WO2003052069A3 (en) 2004-01-29
AU2002360586A1 (en) 2003-06-30
WO2003052069A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
EP1402053A4 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2002357119A8 (en) Mitocidal compositions and methods
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
EP1421384A4 (en) Hprp4s as modifiers of the p53 pathway and methods of use
EP1408978A4 (en) Novel phenylamino-pyrimidines and uses thereof
GB0108470D0 (en) Pharmaceutical compositions and their use
IL154553A0 (en) Urocortin-iii and uses thereof
EP1402262A4 (en) MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
AU2002357748A8 (en) Osteopontin-related compositions and methods
HUP0302867A3 (en) Parasiticidal compositions and methods of their use
PL368321A1 (en) Use of cystathionine
AU2002337916A1 (en) Modifier of the p53 pathway and methods of use
GB0126889D0 (en) Compounds and their uses
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
EP1408985A4 (en) Novel pyridopyrimidones and uses thereof
PT1390074T (en) Novel compositions and uses therefor
EP1414427A4 (en) Kavalactone compositions and methods of use
AU2002360586A8 (en) Flj1115 as modifier of the apaf-1 pathway and methods of use
AU2002359869A8 (en) Pak5-related compositions and methods
EP1392460A4 (en) Hydrogenfluorides of aminosilanols and their use
AU2002337915A1 (en) Ctsls as modifiers of the p53 and apaf-1 pathways and methods of use
AU2002357817A8 (en) Klcs as modifiers of the p53 pathway and methods of use
HU0104370D0 (en) Honeyed schnaps of oerseg
GB0124023D0 (en) Novel compositions and use
GB0119353D0 (en) Novel composition and use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase